Skip to Main Content

Novartis CGXV813B12201

About the Study

For adults experiencing an exacerbation of schizophrenia symptoms who require inpatient treatment

The purpose of this study is to assess the safety, tolerability, and efficacy of GXV813 on treating adults living with symptoms of schizophrenia.

This study is sponsored by Novartis.

Eligibility

You may be eligible to participate in this study if you:

  • are between the ages of 18-65 years old

  • have a diagnosis of schizophrenia based on DSM-5 criteria, confirmed by SCID-5-CT

  • are experiencing an exacerbation of schizophrenia symptoms, with onset symptoms occurring less than 2 months prior to screening

  • are able to discontinue your antipsychotic medication for the duration of the study

  • have a reliable informant to participate in the screening, baseline, and end-of-study assessments

  • are willing to stay in our overnight 24-hour observation unit for the 6-week treatment period

If chosen for this study, you will be compensated for every study visit that you complete and we can provide transportation if needed.

If you are interested in participating in this clinical trial, please call our friendly staff at 773-989-8313 ext. 116 today. You can also fill out the contact form below.